Seeking Alpha

Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference

SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research ...
Seeking Alpha

Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

SALT LAKE CITY, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will showcase 10 studies ...
StockStory.org on MSN

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 3.7% in the afternoon session after the company signed ...
Nasdaq

Myriad Genetics (MYGN) Expands in MRD Testing With New Collab

Myriad Genetics, Inc. MYGN recently announced an agreement with Personalis, Inc. to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The latest ...
Nasdaq

Myriad Genetics Launches "Know More Sooner" Educational Website for Prenatal Genetic Testing

Myriad Genetics, Inc. has launched a new educational website called "Know More Sooner," aimed at providing detailed information about reproductive and prenatal genetic testing. The site seeks to ...
Business Insider

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) ...
Enid News & Eagle

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with ...

SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Flatiron Health, a ...

Looking at the Narrative for Myriad Genetics After Price Target Revisions and Growth Concerns

Myriad Genetics has seen its price target nudged higher even as the core fair value estimate stays flat at about $8.52 per share, reflecting a cautious acknowledgment of recent operational progress.
Express Healthcare

Zydus partners with Myriad Genetics to launch cancer-risk assessment diagnostic tests in India

Zydus Lifesciences, an innovation-led life-sciences company with an international presence, has signed an agreement with ...
Hosted on MSN

Why Myriad Genetics (MYGN) Stock Is Down Today

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 36% in the afternoon session after the company reported mixed first quarter 2025 results: it lowered its full-year revenue, EPS, ...
ABC News

Biotech Company and Patients Face Off to Gain Access to Their Genetic Tests

Myriad gave patients access to their genes after ACLU planned to file complaint. — -- A Utah-based biotech company that had refused to let four patients access their full genetic information has ...